The key aim was to evaluate the efficacy with the vaccine versus placebo in reducing cocaine use. Secondary aims provided confirming vaccine immunogenicity as a result of IgG anti-cocaine antibody ranges and evaluating the safety and tolerability of vaccination via a 20 7 days examine and at 24 7 days https://actonl630yvr5.bloggerswise.com/profile